Announcement on Convening the 2025 Semi-annual Performance Briefing
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening the 2025 Semi-annual Performance Briefing
Filed with SSE · · 3 pages · Chinese
Release
Zhejiang East Asia Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang East Asia Pharmaceutical
- Announcement on Resolutions of the 10th Meeting of the 4th Board of Directors
- Announcement on the Implementation of Repurchase and Cancellation of Partial Equity Incentive Restricted Stocks
- Semi-annual Earnings Preannouncement for 2025
- Announcement on Wholly-owned Subsidiary Obtaining CNAS (China National Accreditation Service for Conformity Assessment) Laboratory Accreditation Certificate
- Announcement on Resolutions of the 8th Meeting of the 4th Board of Supervisors
Later from Zhejiang East Asia Pharmaceutical
- Announcement on Receipt of Decision on Administrative Supervision Measures from Zhejiang Office of China Securities Regulatory Commission
- Announcement on Adjusting the Use of the R&D Center Construction Project in the Initial Public Offering Fundraising Projects
- Announcement on Convening Performance Briefing for Q3 2025
- Announcement on Using Temporarily Idle Self-owned Funds for Entrusted Wealth Management
- Announcement on Resolutions of the 13th Meeting of the 4th Board of Directors
Follow Zhejiang East Asia Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang East Asia Pharmaceutical